Overview

Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19

Status:
Recruiting

Trial end date:
2021-04-30

Target enrollment:

Participant gender:

Summary

SAINT-PERU is a triple-blinded, randomized placebo-controlled trial with two parallel arms to evaluate the efficacy of ivermectin in negativizing nasopharyngeal PCR in patients with SARS-CoV-2 infection. The trial is conducted in two national hospitals at Lima-Peru.

Phase:

Phase 2

Details

Lead Sponsor:

Universidad Peruana Cayetano Heredia

Collaborator:

Barcelona Institute for Global Health

Treatments:

Ivermectin